Free tool
FAERS Monitor: Decitabine
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205582 or its brand name (Decitabine, Decitabine). Reports on generic versions are filed under their own applications.
Reports
4,367
Serious
4,145
95% of reports
Hospitalization
1,567
Death reported
1,166
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use508
- febrile neutropenia456
- myelosuppression438
- drug ineffective349
- neutropenia334
- pneumonia325
- thrombocytopenia291
- death287
- pyrexia263
- acute myeloid leukaemia242
- anaemia218
- product use in unapproved indication218
- sepsis207
- disease progression192
- nausea183
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 7 |
| 2008 | 11 |
| 2009 | 43 |
| 2010 | 29 |
| 2011 | 123 |
| 2012 | 132 |
| 2013 | 86 |
| 2014 | 75 |
| 2015 | 75 |
| 2016 | 103 |
| 2017 | 172 |
| 2018 | 249 |
| 2019 | 322 |
| 2020 | 491 |
| 2021 | 451 |
| 2022 | 517 |
| 2023 | 452 |
| 2024 | 367 |
| 2025 | 343 |
| 2026 | 317 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,792 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute myeloid leukaemiaSignal | 242 | 75.9 | 67.1 | 17,560 |
| myelosuppressionSignal | 438 | 59.3 | 54.2 | 24,775 |
| febrile neutropeniaSignal | 456 | 33.3 | 30.5 | 14,215 |
| thrombocytopeniaSignal | 291 | 12.6 | 11.2 | 3,094 |
| neutropeniaSignal | 334 | 11.9 | 10.7 | 3,323 |
| sepsisSignal | 207 | 9.0 | 7.8 | 1,459 |
| disease progressionSignal | 192 | 7.8 | 6.8 | 1,141 |
| anaemiaSignal | 218 | 5.5 | 4.8 | 807 |
| pneumoniaSignal | 325 | 4.8 | 4.4 | 1,000 |
| product use in unapproved indicationSignal | 218 | 4.2 | 3.7 | 542 |
| pyrexiaSignal | 263 | 3.7 | 3.3 | 515 |
| off label useSignal | 508 | 2.8 | 2.6 | 609 |
| death | 287 | 1.6 | 1.4 | 68 |
| drug ineffective | 349 | 1.3 | 1.2 | 22 |
| nausea | 183 | 1.1 | 1.0 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.